Novo Nordisk Faces a Double Squeeze: Lilly’s Record-Breaking Data and a High-Stakes Court Date
Eli Lilly has thrown down a fresh gauntlet in the GLP-1 arms race, unveiling late-stage data that shows…
Novo Nordisk: A Stock Caught Between Eli Lilly’s Shadow and an AI-Led Renaissance
Novo Nordisk’s shares are nursing a near-47% loss over the past year, and the latest clinical data did…
Novo Nordisk Juggles Lilly’s Clinical Challenge and Wegovy’s Indian Opportunity
Novo Nordisk’s stock barely moves as Eli Lilly’s superior trial data pressures GLP-1 business, but India’s Wegovy approval…
Novo Nordisk’s Oral Pill Crushes Lilly’s Foundayo in Prescription Race, but a 50% Stock Rout Tel
Eli Lilly’s Foundayo trails Novo Nordisk’s oral Wegovy in weekly scripts; Novo faces stock slump but scores pediatric…
Novo Nordisk’s Subscription Gamble Meets a Formidable New Rival
Novo Nordisk shares fall 50% from highs as Eli Lilly’s oral GLP-1 pill challenges Wegovy. The firm launches…
Novo Nordisk’s AI Gambit Meets a Brutal Price War
Novo Nordisk partners with OpenAI to counter Eli Lilly’s tech edge while slashing prices in a fierce weight-loss…
Novo Nordisk’s Subscription Strategy to Counter Market Pressures
Novo Nordisk counters revenue decline and Eli Lilly’s market lead with a Wegovy subscription model, aiming to lock…
Novo Nordisk Faces Mounting Challenges as Competition Intensifies
Novo Nordisk cuts 2026 sales outlook amid generic competition in India, U.S. price pressures, and Eli Lilly’s new…
Novo Nordisk Navigates Pricing Pressures with Strategic Pivot
Novo Nordisk slashes prices in some markets and launches Wegovy subscriptions as new clinical data shows edge over…
Novo Nordisk Navigates Pricing Pressures with Strategic Pivot
Novo Nordisk slashes prices in some markets and launches Wegovy subscriptions as new clinical data shows edge over…